Postpartum Depression (PPD)NCT07766161
Informing Implementation of a Circadian-Focused Intervention for Postpartum Depression
A study testing Light therapy in people with Postpartum Depression (PPD), run by University of Michigan at 1 site in United States.
Trial summary
The proposed study is an open-label trial of Re-Timer® wearable morning bright light therapy for postpartum depression. The study is focused on evaluating the feasibility, acceptability, and implementation context of morning Bright Light Treatment (mBLT) for postpartum depression. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Postpartum Depression (PPD)
- What is being tested?
- Light therapy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- 29 Jul 2026to May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ≤ 6 months postpartum
- EPDS score >10
Who cannot join
- Current or past-year substance use disorder
- Lifetime history of bipolar disorder or psychotic disorder
- Active suicidal intent
- Retinal pathology or history of eye surgery
- Current use of photosensitizing medications
- Untreated sleep-disordered breathing, untreated restless legs syndrome, or narcolepsy
- Psychotherapy or psychotropic medications started/dose changed in past month (psychotherapy started and/or current medication at stable dose ≥ 4 weeks are permitted)
- Medical conditions contraindicated for mBLT (e.g., epilepsy/seizures)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Michigan
Ann Arbor, Michigan, 48109
Kelley DuBuc, 734-764-1904, dubuck@med.umich.edu
Leslie Swanson, PhD
About this study
The proposed study is an open-label trial of Re-Timer® wearable morning bright light therapy for postpartum depression. The study is focused on evaluating the feasibility, acceptability, and implementation context of morning Bright Light Treatment (mBLT) for postpartum depression.
Read the detailed description
This study will test a consumer health light therapy device (Re-Timer)
- Conditions
- Postpartum Depression (PPD)
- Being tested
- Light therapy
- Keywords
- Circadian rhythm, Light therapy
- Medical subject headings
- Depression, Postpartum
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Light therapyDevice
Participants will use the Re-Timer daily for 5 weeks (approximately 35 days). All participants will be provided with a "light therapy window" during which they will wear the device for 60 mins.
| Study group | Role | What they receive |
|---|---|---|
| Light therapy | Experimental | Participants in the arm will be approximately 30 women who are within 6 months postpartum and have an Edinburgh Postnatal Depression Scale (EPDS) score > 10. Receives: Device: Light therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Retention rate
Number of participants who enrolled/number of participants who completed trial ( ≥70% acceptable)
Measured: At approximately 5 weeks after treatment is started (post-treatment)
Adherence rate (as assessed through self-report)
Percent of participants who completed ≥70% light therapy intervention sessions
Measured: At approximately 5 weeks after treatment is started (post-treatment)
Secondary outcomes (2)
Client Satisfaction Scale (CSS) score
The Client Satisfaction Scale measures satisfaction with the treatment. Total scores range from 5-20; higher total scores indicate greater treatment satisfaction.
Measured: At approximately 5 weeks after treatment is started (post-treatment)
Treatment Satisfaction Scale (TSS) score
The Treatment Satisfaction Scale measures the acceptability of the treatment. Total scores range from 2 to 20 ; higher scores indicate greater treatment acceptability.
Measured: At approximately 5 weeks after treatment is started (post-treatment)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2026
- Study start29 Jul 2026
- Primary completionMay 2027 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Postpartum Depression (PPD)Studies of the same condition, open and under way.
- More trials run by University of MichiganThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Michigan
- Sponsor type
- University, hospital or other
- Collaborators
- American Academy of Sleep Medicine
- Responsible party
- Principal investigator, Leslie Swanson, University of Michigan
- Investigators
- Leslie Swanson, PhD, Principal investigator, University of Michigan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07766161
- Sponsor's protocol ID
- HUM00285407
- Status last verified
- Aug 2026
- First submitted
- 5 Aug 2026
- Last updated
- 14 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Informing Implementation of a Circadian-Focused Intervention for Postpartum Depression
- ClinicalTrials.gov ID
- NCT07766161
- Acronym / sponsor ID
- HUM00285407
- Conditions
- Postpartum Depression (PPD)
- Keywords
- Circadian rhythm, Light therapy
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- University of MichiganUniversity, hospital or other
- Collaborators
- American Academy of Sleep Medicine
- Study start
- 29 Jul 2026 (actual)
- Primary completion
- May 2027 (estimated)
- Study completion
- May 2027 (estimated)
- First posted
- 14 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The proposed study is an open-label trial of Re-Timer® wearable morning bright light therapy for postpartum depression. The study is focused on evaluating the feasibility, acceptability, and implementation context of morning Bright Light Treatment (mBLT) for postpartum depression.
Detailed description
This study will test a consumer health light therapy device (Re-Timer)
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Light therapy | Experimental | Device: Light therapyParticipants in the arm will be approximately 30 women who are within 6 months postpartum and have an Edinburgh Postnatal Depression Scale (EPDS) score > 10. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- ≤ 6 months postpartum
- EPDS score >10
Key exclusion criteria (8 listed)
- Current or past-year substance use disorder
- Lifetime history of bipolar disorder or psychotic disorder
- Active suicidal intent
- Retinal pathology or history of eye surgery
- Current use of photosensitizing medications
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Light therapyParticipants will use the Re-Timer daily for 5 weeks (approximately 35 days). All participants will be provided with a "light therapy window" during which they will wear the device for 60 mins. | Device | Light therapy |
Primary outcome
Retention rate
Time frame: At approximately 5 weeks after treatment is started (post-treatment)
Number of participants who enrolled/number of participants who completed trial ( ≥70% acceptable)
Adherence rate (as assessed through self-report)
Time frame: At approximately 5 weeks after treatment is started (post-treatment)
Percent of participants who completed ≥70% light therapy intervention sessions
2 secondary outcomes
Client Satisfaction Scale (CSS) score
Time frame: At approximately 5 weeks after treatment is started (post-treatment)
Treatment Satisfaction Scale (TSS) score
Time frame: At approximately 5 weeks after treatment is started (post-treatment)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Postpartum Depression (PPD)
Recruiting
Restoring Emotional Needs With Exogenous Ketones for Women With Postpartum Depression
Postpartum Depression (PPD)
Recruiting
Treatment With Repetitive Transcranial Magnetic Stimulation in Peripartal Depression
Depression During Pregnancy, Postpartum Depression (PPD)
RecruitingEarly Phase 1
A Web-based Intervention Program for Postpartum Depression
Postpartum Depression (PPD), Web-based Intervention
Recruiting
The Goal is to Examine the Impact of Doula-delivered, Nurse-coordinated Postpartum Care Among Individuals With Preterm Births <34 Weeks' Gestation Requiring NICU Admission.
Doula Support, Postpartum
Not yet recruitingObservational study
AI-Enabled Wearable Monitoring for Detection of Postpartum Depression and Anxiety
Postpartum Depression (PPD), Postpartum Anxiety
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Leslie Swanson, PhD principal investigator
University of Michigan
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Light therapy in people with Postpartum Depression (PPD), run by University of Michigan at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Kelley DuBuc (734-764-1904, dubuck@med.umich.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Retention rate (time frame: At approximately 5 weeks after treatment is started (post-treatment)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.